Details for Patent: 9,987,229

Which drugs does patent 9,987,229 protect, and when does it expire?

Patent 9,987,229 protects AIRDUO DIGIHALER and AIRDUO RESPICLICK and is included in one NDA.

Protection for AIRDUO DIGIHALER has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eleven patent family members in eleven countries.

Summary for Patent: 9,987,229

Title:	Process for preparing a medicament
Abstract:	The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles having an agglomerate particle size such that the agglomerate is capable of passing through a sieve having a mesh of 50-3000 .mu.m with a pharmaceutically acceptable particulate carrier, and (b) mixing the resultant material in a mixer to break up the agglomerate into primary particles dispersed in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient exists as primary particles having a particle size of 50 .mu.m or less.
Inventor(s):	Zeng; Xian-Ming (London, GB), Tee; Seah Kee (London, GB)
Assignee:	Norton Healthcare Ltd. (London, GB)
Application Number:	15/453,940
Patent Claim Types: see list of patent claims	Composition; Compound; Process; Delivery;

Drugs Protected by US Patent 9,987,229

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Teva Pharm	AIRDUO DIGIHALER	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-004	Jul 12, 2019		RX	Yes	No					Y
Teva Pharm	AIRDUO DIGIHALER	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-005	Jul 12, 2019		RX	Yes	No					Y
Teva Pharm	AIRDUO DIGIHALER	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-006	Jul 12, 2019		RX	Yes	No					Y
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-001	Jan 27, 2017		RX	Yes	No					Y
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-002	Jan 27, 2017		RX	Yes	No					Y
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-003	Jan 27, 2017		RX	Yes	Yes					Y

International Family Members for US Patent 9,987,229

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	498394
Canada	2575957
Cyprus	1113221
Germany	602004031459
Denmark	1699434
European Patent Office	1699434
Spain	2362038